Stocks in the Sweet Spot for Bear Market Growth (SWAV, SOBR, MDT, ZBH, ISRG, IRTC, ZYXI)

Health technology offers an extremely compelling risk/reward profile for investors focused on the long-term portfolio time horizon. However, given this year’s bear market, it also may now represent a compelling opportunity for speculators participating on a swing or intermediate time horizon.
Health technology plays, such as medical device stocks, diagnostic technology, and substance abuse identification technology, sit at the intersection of the healthcare sector and the growth technology space, offering a balance between non-cyclical demand and structural growth.
It’s a sweet spot that may offer a port in the storm as this year’s bear market bargain sale continues to play out.
With that in mind, we take a look below at a few of the most interesting stocks building value and growth potential in this compelling niche.

Shockwave Medical Inc. (Nasdaq:SWAV) Shockwave Medical, Inc. operates as a medical device company, which focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease, C2 catheters for treating coronary artery disease, and S4 catheters or treating below-the-knee peripheral artery disease. The company was founded by Daniel Hawkins, John M. Adams, and Todd J. Brinton on June 17, 2009 and is headquartered in Santa Clara, CA.
Shockwave Medical Inc. (Nasdaq:SWAV) recently announced that it has initiated the first-ever prospective coronary intervention study consisting of all female patients – EMPOWER CAD – to determine whether the positive results from earlier coronary IVL studies with the Shockwave C2 Coronary IVL Catheter, which showed similar safety outcomes across both sexes, can be replicated in an expanded, ‘real-world’ population of female patients with severely calcified coronary lesions. This prospective, multicenter registry will enroll up to 400 female patients with symptomatic ischemic heart disease in up to 50 investigational centers in the United States and Europe and will include a 3-year follow-up.
“When it comes to coronary artery disease (CAD), females are often under-investigated, under-treated and have less favorable outcomes than males due to a variety of different factors,” said Dr. McEntegart. “Previous reports with atherectomy have shown that females with calcified CAD are more susceptible to adverse procedural outcomes compared to males. Despite often being more challenging to treat, female patients are under-represented in published data, and there have been no dedicated prospective studies performed on this population. EMPOWER CAD will be an extremely valuable study to better inform interventional cardiologists on the optimal treatment strategy for these complex patients.”
Traders will note 9% during the past week in terms of shareholder gains in the listing. Market participants may want to pay attention to this stock as transaction volume levels have recently pushed 10% over what the stock has registered over the longer term.
Shockwave Medical Inc. (Nasdaq:SWAV) has a significant war chest ($224.9M) of cash on the books, which must be weighed relative to about $66.2M in total current liabilities. One should also note that debt has been growing over recent quarters. SWAV is pulling in trailing 12-month revenues of $363.7M. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 116%.

SOBR Safe Inc. (Nasdaq:SOBR) is a very interesting device play in the substance detection marketplace. The company has developed a potentially revolutionary touch-based device that instantly detects alcohol levels. It’s totally non-invasive and can be deployed to ensure alcohol-induced accidents are entirely prevented in industrial use cases including factory floors, bus fleets, cargo trucking, and other similar applications.
According to company materials, other intended applications include managed care and young drivers. This patent-pending alcohol detection solution helps prevent an intoxicated worker from taking the factory floor; or a driver, the vehicle keys.
SOBR Safe Inc. (Nasdaq:SOBR) most recently announced the closing of a $6 million private placement deal with Aegis Capital Corp. acting as Exclusive Placement Agent.
SOBR management reports that the company issued more than 1.9 million units and 2.1 million pre-funded units at a purchase price of $1.48 a unit. Each unit consists of one share of stock and a non-tradable warrant to buy another share at $1.35. The private placement was priced Sept. 28 and formally closed last Friday. The shares opened at $2.85 on Monday morning and soared from there.
SOBR also recently announced that it has executed on its judicial sales strategy, signing three reseller agreements with national distributors. These agreements provide access to large, established customer networks for the purpose of replacing breathalyzers in the American judicial market following SOBR’s recent successes in a leading residential reentry center.
SOBR Safe Inc. (Nasdaq:SOBR) Chairman & CEO Dave Gandini explained, “Distributors are a key force multiplier for SOBRsafe. They have established, trust-based relationships with their customers – all of whom are demonstrated alcohol detection buyers in pursuit of advanced solutions. Our distributors are introducing us to progressive, motivated decision makers, accelerating our market penetration at no fixed cost to SOBRsafe. We look forward to reporting their adoption success to our shareholders.”

Medtronic PLC (NYSE:MDT) is a health technology company that engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through its Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit segments.
The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables.
Medtronic PLC (NYSE:MDT) recently announced the LINQ II™ Insertable Cardiac Monitor (ICM) system is the first-and-only ICM to receive 510(k) clearance by the U.S. Food and Drug Administration (FDA) for use in pediatric patients over the age of 2 who have heart rhythm abnormalities and require long-term, continuous monitoring.
“For pediatric cardiologists who see many young patients needing continuous, long-term monitoring for infrequent or unknown heart rhythm conditions, this expanded indication for the LINQ II ICM is critically important,” said Jennifer Silva, M.D., director of pediatric cardiac electrophysiology at Washington University in St. Louis and St. Louis Children’s Hospital. “The data generated from these small monitors can help us better tailor treatment decisions and ongoing management for our patients.”
It will be interesting to see if the stock can break out of its recent sideways action. Over the past week, the stock is net flat, and looking for something new to spark things. Over the past month, shares of the stock have suffered from clear selling pressure, dropping by roughly -5%.
Medtronic PLC (NYSE:MDT) managed to rope in revenues totaling $7.4B in overall sales during the company’s most recently reported quarterly financial data — a figure that represents a rate of top line growth of -7.7%, as compared to year-ago data in comparable terms. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($8.9B against $14B, respectively).

Other key stocks in the health technology niche include Zimmer Biomet Holdings Inc. (NYSE:ZBH), Intuitive Surgical Inc. (Nasdaq:ISRG), iRhythm Technologies Inc. (Nasdaq:IRTC), and Zynex Inc. (Nasdaq:ZYXI).

For consideration of being featured on WallstreetPR, contact:

Please make sure to read and completely understand our disclaimer at FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at

Published by Brendan Byrne

While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email ( or his Google+ page (